Pharmaconex West Africa, the latest expansion of the successful Pharmaconex event series, will take place from 22-24 April 2024 at the Landmark Centre in Lagos, Nigeria.

The event will focus on Active Pharmaceutical Ingredients (APIs) & Generic APIs, Machinery & Process, Packaging Materials, and Finished Dosage Forms (FDF) and is open to all businesses involved in the pharmaceutical and medical laboratory sectors, including manufacturers, distributors, suppliers, consultants, researchers, and regulators.

Unless you have never taken a pharmaceutical drug in your life, then you have taken an Active Pharmaceutical Ingredient (API). All drugs are made up of two things: the major active ingredient which is the API and an excipient which is an inactive compound that can be thought of as a carrier component. APIs are found in both over-the-counter and prescription medication. In generic (non-name brand) medications, the name of the API is also the name of the product.

Source: Pharmaconex Blog

First founded in 2019 as a new regulatory body independent from Egypt’s Ministry of Health, the Egyptian Drug Authority (EDA) has made significant progress over the last three years. Now recognised as one of the MEA region’s leading regulators, the EDA can point to several notable successes in Egypt’s battle against the COVID-19 pandemic.

Source: Pharmaboardroom

Complying with Irish takeover rules, Amgen alerted the London Stock Exchange Friday that “any offer by Amgen for Horizon is, or is likely to be, solely in cash.” Naturally, the company caveated that there can “be no certainty” an offer will materialize.

Source: FIERCE Pharma

Dec 1 (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics (YMAB.O) for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% inextended trading.

Source: Reuters

“Local pharma manufacturing in the MENA region represents between 32-57 percent of the consumed pharma packages. Egypt is one of the pioneering countries in terms of pharma industry localisation compared to other countries in the region, as local pharma production to consumption ratio in the Egyptian market is over 65 percent,”

Source: Ahram Online

Under the umbrella of its Vision 2030 economic transformation plan, Egypt is making strides towards covering its over 100 million citizens through a universal healthcare insurance scheme that has already been rolled out on a pilot basis in certain areas of the country.

Source: Pharmaboardroom

"The exhibition provides great opportunities to build relationships with prospects and existing clients as well as form new business networks," said Ahmed Hany, an engineer with Cairo-based Nama Group, which is an agent, distributor, and producer of quality products including medicines.

Source: Xinhua

July 15 (Reuters) - The U.S. government has ordered an additional 2.5 million doses of Bavarian Nordic's (BAVA.CO) vaccine for use against monkeypox and expects more later this month to fight an outbreak of the viral disease. 

Source: Reuters

The COVID-19 pandemic has changed the world – and the biopharma industry. The industry has adopted new technologies and approaches to drug development – and has learned that it is possible to bring new therapies to patients in significantly reduced timelines. 

Source: The Medicine Maker

Four years after Egypt enacted a new universal health law, the country’s pharmaceutical market has consolidated itself as the fastest growing in the Middle East and Africa, far outpacing Saudi Arabia, South Africa, the UAE, and Algeria. With USD 6.3 billion in value, Egyptian pharma is about to double its size from 2017. 

Source: Pharma Boardroom

OSLO, July 25 (Reuters) - Danish biotechnology company Bavarian Nordic (BAVA.CO) said on Monday the European Commission had given permission for its Imvanex vaccine to be marketed as protection against monkeypox, as recommended last week by the European Medicines Agency (EMA).

Source: Reuters

The Middle East and Africa (MEA) medtech market is expected to grow from a value of USD 16.6 billion in 2019 to USD 21.8 billion at a CAGR of 3.6 percent by 2027, according to Business Market Insights. Read on for five crucial trends impacting MEA medtech and how the industry stands to evolve in the coming years.

Source: Pharma Boardroom